Skip to main content

Table 1 Clinical and demographical characteristics of PWH according to liver stiffness

From: Circulating levels of endotrophin and cross-linked type III collagen reflect liver fibrosis in people with HIV

 

PWH (all)

PWH without clinical significant fibrosis (Stiffness < 7.1 kPa)

PWH with clinical significant fibrosis (Stiffness ≥ 7.1)

P-value

Total number of participants n (%)

141 (100)

116 (82.3)

25 (17.7)

N.a

Age (years)

47 (24–72)

46 (24–72)

52 (36–67)

0.004

Sex (male/female)

120/21

100/20

20/1

N.s

BMI (kg/cm2)

24 (19–36)

24 (20–36)

24 (19–32)

N.s

AST (U/L)

23 (9–93)

22 (9–65)

27 (11–93)

0.037

ALT (U/L)

29 (10–110)

29 (10–103)

33 (10–110)

N.s

GGT (U/L)

46 (16–302)

45 (16–302)

60 (26–248)

N.s

Thrombocytes

206 (46–400)

213 (123–400)

167 (46–259)

0.0001

Transient elastography (kPa)

4.9 (2.0–49.6)

4.6 (2.0–6.9)

9.3 (7.1–49.6)

N.a

Steatosis CAP (dB/m)

232 (100–378)

231 (100–378)

236 (101–364)

N.s

Cholinesterase

13,264 (7168–24,175)

13,797 (7168–22,233)

11,028 (7567–24,175)

N.s

PC3X (ng/ml)

6.7 (1.5–33.3)

6.5 (1.5–33.3)

7.5 (4.6–30.1)

0.0078

PRO-C5 (ng/ml)

465.0 (130.0–998.4)

463 (130.0–828.5)

476.6 (130.0–998.4)

N.s

PRO-C6 (ng/ml)

6.9 (3.7–22.6)

6.8 (3.7–22.6)

7.9 (5.3–18.5)

0.0003

Anti-HCV-positive (%)

18 (12.8)

11 (9.5)

7 (28.0)

N.s

Hbs-Ag positive (%)

4 (2.8)

3 (2.6)

1 (4.0)

N.s

  1. All values are given as median and range. ALT alanine aminotransferase, AST aspartate aminotransferase, BMI Body-mass index, CAP Controlled attenuation parameter, GGT γ–glutamyl transferase, n.a. not applicable, n.s. not significant
  2. Significant p-values are shown in bold